LAM-002 is an exquisitely selective first-in-class kinase inhibitor that is cytotoxic for specific cancers with little to no effect on normal cells. LAM Therapeutics advanced LAM-002 into a Phase 1 trial in relapsed or refractory B-cell non-Hodgkin lymphoma within one year of discovery (Company Pipeline, LAM Therapeutics, APR 14, 2016, View Source [SID:1234510762]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

LAM-002 is also being evaluated in pre-clinical models of neurological disease.